GO:0031780 corticotropin hormone receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031780 (corticotropin hormone receptor binding) is a molecular function defined as binding to a corticotropin hormone receptor, with synonyms including ACTH receptor binding and adrenocorticotropin receptor binding.
• This binding event is a critical step in the hypothalamic-pituitary-adrenal (HPA) axis, where ligands such as corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) interact with their receptors to regulate cortisol production.
• The term encompasses interactions of CRH with CRHR1 and CRHR2, as well as ACTH with MC2R, and is modulated by the CRH-binding protein (CRHBP).
• Dysregulation of corticotropin hormone receptor binding is implicated in stress-related disorders, anxiety, and metabolic conditions, with glucocorticoids providing negative feedback.
• Research methods to study this function include binding assays, receptor autoradiography, CRISPR knockout/knock-in models, and transcriptomic profiling.
• EDITGENE offers CRISPR-based services to interrogate genes involved in corticotropin hormone receptor binding, enabling mechanistic and therapeutic discoveries.
Description
Corticotropin hormone receptor binding (GO:0031780) is a molecular function that describes the binding of a ligand to a corticotropin hormone receptor. This term is central to neuroendocrine research because it underlies the first steps of the hypothalamic-pituitary-adrenal (HPA) axis response to stress. The HPA axis is a major neuroendocrine system that controls reactions to stress and regulates many body processes, including digestion, the immune system, mood and emotions, sexuality, and energy storage and expenditure. The binding of corticotropin-releasing hormone (CRH) to its receptors (CRHR1 and CRHR2) and the subsequent binding of adrenocorticotropic hormone (ACTH) to the melanocortin 2 receptor (MC2R) are key events in this cascade. Understanding the molecular details of these interactions is essential for deciphering how organisms respond to stress and how dysfunction contributes to disease. Researchers studying stress-related disorders, anxiety, and metabolic syndromes often focus on the proteins involved in corticotropin hormone receptor binding as potential therapeutic targets. Moreover, the regulation of these binding events by glucocorticoids and binding proteins such as CRHBP adds another layer of complexity. This article provides a comprehensive overview of the ontology, mechanisms, key genes, and research methodologies associated with GO:0031780, with a focus on how CRISPR-based models can accelerate discovery.
corticotropin hormone receptor binding At A Glance
| GO ID | GO:0031780 |
|---|---|
| GO term | corticotropin hormone receptor binding |
| Ontology | molecular_function |
| Synonym | ACTH receptor binding; adrenocorticotropic hormone receptor ligand; adrenocorticotropin hormone receptor binding; adrenocorticotropin receptor binding; corticotropin receptor binding |
| Major function | Binding to a corticotropin hormone receptor, initiating neuroendocrine signaling |
| Related receptors | CRHR1, CRHR2, MC2R |
| Related ligands | CRH, ACTH, UCN1, UCN2, UCN3 |
| Associated diseases | Stress-related disorders, anxiety, depression, obesity, adrenal insufficiency |
What Is GO:0031780?
According to the Gene Ontology, GO:0031780 (corticotropin hormone receptor binding) is defined as the binding to a corticotropin hormone receptor. This molecular function encompasses the interaction between a ligand (such as corticotropin-releasing hormone or adrenocorticotropic hormone) and its specific receptor (such as CRHR1, CRHR2, or MC2R). It is a binding event that initiates signaling cascades, typically leading to the activation of adenylyl cyclase and increased cAMP levels. The term is synonymous with ACTH receptor binding, adrenocorticotropic hormone receptor ligand, adrenocorticotropin hormone receptor binding, adrenocorticotropin receptor binding, and corticotropin receptor binding. It is classified under the molecular_function aspect of the Gene Ontology.
Why Is corticotropin hormone receptor binding Important in Cell Biology?
Corticotropin hormone receptor binding is a fundamental molecular event in the neuroendocrine stress response. It governs the activation of the HPA axis, which is essential for maintaining homeostasis under stress. Dysregulation of this binding process has been linked to a variety of human pathologies, including anxiety disorders, major depression, and metabolic syndrome. Furthermore, glucocorticoid negative feedback, which depends on proper receptor binding, is critical for terminating the stress response and preventing chronic exposure to stress hormones. Therefore, understanding the molecular determinants of corticotropin hormone receptor binding is not only of basic scientific interest but also has significant clinical implications for developing targeted therapies.
• Central to the HPA axis stress response, regulating cortisol production.
• Involved in anxiety-like behavior, as shown by antisense targeting of CRHR1.
• Modulated by CRH-binding protein (CRHBP), which sequesters CRH and alters receptor binding.
• Glucocorticoids downregulate CRHBP binding in plasma, providing feedback regulation.
• Proton sensitivity of CRHR1 affects POMC expression, linking pH to receptor binding.
• Quercetin suppresses acute stress-induced HPA axis response, potentially via receptor binding.
• Implicated in adrenal insufficiency and Cushing's syndrome through MC2R mutations.
• Target for drug development in depression and anxiety disorders.
• Key to understanding sex differences in stress responses.
• Provides a model for studying G-protein coupled receptor (GPCR) binding mechanisms.
Molecular Mechanism of corticotropin hormone receptor binding
Ligand-Receptor Interaction
In simple terms: This is the first step where a hormone locks onto its receptor like a key in a lock.
Corticotropin hormone receptor binding involves the specific interaction between a ligand, such as corticotropin-releasing hormone (CRH) or adrenocorticotropic hormone (ACTH), and its cognate receptor. CRH binds to CRHR1 and CRHR2, which are class B G-protein coupled receptors (GPCRs), while ACTH binds to MC2R, a class A GPCR. This binding is characterized by high affinity and specificity, and it triggers conformational changes in the receptor that activate intracellular signaling pathways, primarily the cAMP/PKA pathway. The binding affinity can be modulated by accessory proteins like CRHBP, which binds CRH and prevents its interaction with receptors.
Receptor Activation and Signaling
In simple terms: Once the hormone binds, the receptor switches on a signal inside the cell.
Upon ligand binding, CRHR1 and CRHR2 undergo conformational changes that lead to the activation of Gs proteins, which in turn stimulate adenylyl cyclase, increasing intracellular cAMP levels. This activates protein kinase A (PKA) and other downstream effectors, ultimately leading to the transcription of target genes such as proopiomelanocortin (POMC). MC2R, upon ACTH binding, also signals via cAMP/PKA, but its trafficking to the cell surface requires the melanocortin 2 receptor accessory protein (MRAP). The signaling is tightly regulated by phosphorylation, desensitization, and internalization of the receptors.
Regulation by Glucocorticoids
In simple terms: Stress hormones can turn down their own production by reducing the binding of CRH to its receptor.
Glucocorticoids, the end products of the HPA axis, exert negative feedback at multiple levels, including the pituitary and hypothalamus. They decrease the binding of CRH to its receptor by downregulating CRHR1 expression and by increasing the expression of CRHBP, which sequesters CRH. This feedback loop is essential for preventing excessive HPA axis activation and maintaining homeostasis. Glucocorticoid receptor regulation itself is complex and involves interactions with other transcription factors.
Modulation by pH and Other Factors
In simple terms: The acidity of the environment can change how well the hormone binds to its receptor.
Recent studies have shown that CRHR1 signaling is sensitive to extracellular pH. In male mice, proton sensitivity of CRHR1 affects POMC expression, suggesting that local pH changes in the pituitary can modulate corticotropin hormone receptor binding and downstream effects. Other factors, such as quercetin, a flavonoid, have been shown to suppress acute stress-induced HPA axis response, potentially by interfering with receptor binding or signaling. These findings highlight the complexity of the regulatory mechanisms governing this binding event.
Key Genes Involved in GO:0031780 corticotropin hormone receptor binding
The following genes encode proteins that are directly involved in or regulate corticotropin hormone receptor binding, including ligands, receptors, and binding proteins.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CRH | Ligand for CRHR1 and CRHR2 | Central to stress response; knockout models show altered anxiety |
| CRHR1 | Receptor for CRH; mediates HPA axis activation | Target for anxiety and depression; antisense knockdown reduces anxiety |
| CRHR2 | Receptor for CRH and urocortins; modulates stress coping | Implicated in cardiovascular and metabolic functions |
| MC2R | Receptor for ACTH; essential for cortisol synthesis | Mutations cause familial glucocorticoid deficiency |
| CRHBP | Binds CRH and prevents receptor activation | Regulates CRH bioavailability; glucocorticoids decrease its binding |
| POMC | Precursor of ACTH and other peptides | Regulated by CRHR1 signaling; proton sensitivity affects expression |
| MRAP | Accessory protein for MC2R trafficking | Required for MC2R function; mutations cause FGD |
| UCN1 | Ligand for CRHR1 and CRHR2 | Involved in stress and anxiety |
| UCN2 | Ligand for CRHR2 | Modulates cardiovascular function |
| UCN3 | Ligand for CRHR2 | Regulates energy balance |
| NR3C1 | Glucocorticoid receptor; mediates negative feedback | Downregulates CRH and CRHR1; regulated by glucocorticoids |
| NR3C2 | Mineralocorticoid receptor | Modulates HPA axis sensitivity |
| AVP | Arginine vasopressin; synergizes with CRH | Co-secreted with CRH; enhances ACTH release |
| AVPR1B | Receptor for AVP in pituitary | Modulates ACTH secretion |
| GNA S | Gs alpha subunit; couples receptors to adenylyl cyclase | Mediates cAMP signaling upon receptor binding |
| ADCYAP1 | PACAP; modulates CRH and ACTH | Involved in stress adaptation |
| FKBP5 | Co-chaperone of glucocorticoid receptor | Regulates glucocorticoid sensitivity; implicated in depression |
How Is corticotropin hormone receptor binding Regulated?
The binding of corticotropin hormones to their receptors is regulated at multiple levels. Glucocorticoids exert negative feedback by decreasing CRH binding to CRHR1 and increasing CRHBP expression. The CRH-binding protein (CRHBP) itself is regulated by glucocorticoids, which decrease its binding in human plasma. Additionally, receptor levels are controlled by transcriptional and post-transcriptional mechanisms, including antisense targeting that reduces CRHR1 levels and anxiety-like behavior. Proton sensitivity of CRHR1 provides a local regulatory mechanism in the pituitary. Furthermore, dietary factors such as quercetin can suppress acute stress-induced HPA axis response, potentially by modulating receptor binding or signaling. These regulatory mechanisms ensure that the HPA axis responds appropriately to stress and returns to baseline.
corticotropin hormone receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CRHR1 | Anxiety, depression | CRHR1 knockout mice; antisense knockdown |
| MC2R | Familial glucocorticoid deficiency | MC2R point mutation knock-in mice |
| CRHBP | Stress-related disorders, metabolic syndrome | CRHBP overexpression or knockout models |
| POMC | Obesity, adrenal insufficiency | POMC knockout mice; proton sensitivity studies |
| NR3C1 | Cushing's syndrome, depression | Glucocorticoid receptor knockout mice |
Stress-Related Disorders and Anxiety
Dysregulation of corticotropin hormone receptor binding is strongly implicated in anxiety and stress-related disorders. Antisense targeting of CRHR1, which reduces receptor levels and binding, has been shown to reduce anxiety-like behavior in animal models. This suggests that excessive CRH-CRHR1 binding contributes to anxiety pathogenesis. Furthermore, chronic stress and elevated cortisol levels are associated with mood disorders, and CRHBP levels are altered in depressed patients. Targeting the binding interaction between CRH and CRHR1 is a promising therapeutic strategy for anxiety and depression.
Metabolic and Adrenal Disorders
Mutations in MC2R, the receptor for ACTH, cause familial glucocorticoid deficiency, a condition characterized by adrenal insufficiency. Proper ACTH-MC2R binding is essential for cortisol production, and defects in this interaction lead to impaired stress response. Additionally, glucocorticoid negative feedback is critical for metabolic homeostasis; dysregulation of this feedback, as seen in Cushing's syndrome, involves altered receptor binding and signaling. The CRH-binding protein also plays a role in modulating ACTH release, and its dysregulation has been linked to metabolic syndrome.
Neuroendocrine and Inflammatory Conditions
Corticotropin hormone receptor binding is also involved in neuroendocrine and inflammatory responses. CRHR1 is expressed in various brain regions and peripheral tissues, where it modulates inflammation and immune function. Proton sensitivity of CRHR1 affects POMC expression, linking local pH changes to neuroendocrine output. Quercetin, a flavonoid with anti-inflammatory properties, suppresses acute stress-induced HPA axis response, potentially by interfering with receptor binding. These findings suggest that modulating corticotropin hormone receptor binding could have therapeutic benefits in inflammatory and stress-related conditions.
From corticotropin hormone receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CRHR1 knockout reduce anxiety? | CRHR1 knockout mouse |
| How does MC2R mutation affect ACTH binding? | MC2R point mutation knock-in mouse |
| What is the effect of CRHBP overexpression on stress? | CRHBP overexpression transgenic mouse |
| Does proton sensitivity of CRHR1 affect POMC? | CRHR1 knock-in with pH-insensitive mutation |
| Can quercetin modulate HPA axis via receptor binding? | Quercetin-treated rat model |
| What is the role of glucocorticoid feedback? | Glucocorticoid receptor knockout mouse |
How to Study the corticotropin hormone receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Binding affinity and receptor density | Characterizing CRH or ACTH binding to receptors |
| CRISPR knockout | Loss-of-function effects | Studying CRHR1 role in anxiety |
| RNA-seq | Transcriptional changes | Measuring POMC expression after CRHR1 modulation |
| FRET/BRET | Real-time binding and signaling | Screening for receptor modulators |
| Immunohistochemistry | Receptor localization | Mapping CRHR1 in brain regions |
| Western blot | Protein expression and phosphorylation | Assessing receptor downregulation |
| cAMP assay | Downstream signaling activation | Measuring receptor activation upon ligand binding |
| CRISPR knock-in | Introduction of specific mutations | Modeling MC2R mutations in disease |
Binding Assays
Radioligand binding assays using 125I-labeled CRH or ACTH are classic methods to measure corticotropin hormone receptor binding affinity and density. These assays can be performed on membrane preparations from cells or tissues expressing the receptors. Competitive binding assays with unlabeled ligands or antagonists can determine specificity and kinetics. Such methods have been used to study the modulation of CRH binding by glucocorticoids and CRHBP.
Genetic Manipulation and CRISPR
CRISPR/Cas9 technology enables the generation of knockout, knock-in, and point mutation models to study the function of genes involved in corticotropin hormone receptor binding. For example, CRHR1 knockout mice have been used to demonstrate reduced anxiety-like behavior. Point mutations in MC2R can be introduced to mimic human disease mutations and study their effect on ACTH binding. These models provide causal insights that complement correlative studies.
Transcriptomic and Proteomic Profiling
RNA sequencing (RNA-seq) can reveal changes in gene expression following manipulation of corticotropin hormone receptor binding. For instance, proton sensitivity of CRHR1 affects POMC expression, which can be quantified by RNA-seq. Proteomic approaches can identify interacting partners and post-translational modifications of receptors. These high-throughput methods provide a systems-level view of the signaling networks downstream of receptor binding.
Imaging and Live-Cell Assays
Fluorescence resonance energy transfer (FRET) and bioluminescence resonance energy transfer (BRET) sensors can monitor ligand-receptor binding and downstream signaling in live cells. These techniques offer temporal and spatial resolution. They have been used to study GPCR activation, including CRHR1 and MC2R. Such assays are valuable for screening small molecule modulators of corticotropin hormone receptor binding.
How CRISPR Can Be Used to Study GO:0031780 corticotropin hormone receptor binding
Knockout
CRISPR knockout of genes such as CRHR1 or MC2R can abolish corticotropin hormone receptor binding, providing a clean loss-of-function model. For example, CRHR1 knockout mice exhibit reduced anxiety-like behavior, confirming the role of CRHR1 in stress responses. Knockout models are essential for determining the necessity of a gene in the binding process and downstream physiology.
Point Mutation
Point mutations can be introduced via CRISPR to mimic human disease variants or to dissect specific residues involved in ligand binding. For instance, mutations in MC2R that impair ACTH binding cause familial glucocorticoid deficiency. By generating point mutation knock-in mice, researchers can study the precise molecular defects and test potential therapies.
Knock-in
Knock-in of reporter genes or tags (e.g., GFP, HA) allows visualization and purification of receptor complexes. Tagged knock-in of CRHR1 can be used to track receptor trafficking and interactions in live cells. This approach is valuable for understanding the dynamics of corticotropin hormone receptor binding in native contexts.
Overexpression
Overexpression of ligands such as CRH or receptors like CRHR1 can amplify binding and signaling, creating a sensitized background to study downstream effects. For example, CRHBP overexpression can sequester CRH and reduce receptor binding, mimicking a hyporesponsive state. Overexpression models are useful for gain-of-function studies and for testing inhibitors.
How EDITGENE Supports corticotropin hormone receptor binding Research
Researchers studying corticotropin hormone receptor binding-related genes often need to determine whether a candidate gene is causally involved in the binding process or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous mechanistic studies and therapeutic target validation.
Contact EDITGENE today to design your custom CRISPR model for corticotropin hormone receptor binding research.
Frequently Asked Questions About corticotropin hormone receptor binding
What is corticotropin hormone receptor binding?
Corticotropin hormone receptor binding (GO:0031780) is a molecular function defined as the binding to a corticotropin hormone receptor, such as CRHR1, CRHR2, or MC2R, by ligands like CRH or ACTH.
What genes are involved in corticotropin hormone receptor binding?
Key genes include CRH, CRHR1, CRHR2, MC2R, CRHBP, POMC, and MRAP, among others.
How is corticotropin hormone receptor binding regulated?
It is regulated by glucocorticoid negative feedback, CRH-binding protein, pH sensitivity, and factors like quercetin.
What diseases are associated with corticotropin hormone receptor binding?
Dysregulation is linked to anxiety, depression, adrenal insufficiency, and metabolic disorders.
What methods are used to study corticotropin hormone receptor binding?
Common methods include radioligand binding assays, CRISPR knockout/knock-in, RNA-seq, and FRET/BRET.
How does CRISPR help study corticotropin hormone receptor binding?
CRISPR enables knockout, point mutation, knock-in, and overexpression models to test the causal role of specific genes in binding and signaling.
What is the role of CRHR1 in stress?
CRHR1 mediates CRH signaling; its knockdown reduces anxiety-like behavior, highlighting its role in stress responses.
Can corticotropin hormone receptor binding be targeted therapeutically?
Yes, antagonists of CRHR1 are being explored for anxiety and depression, and modulators of MC2R for adrenal disorders.
What is the HPA axis?
The hypothalamic-pituitary-adrenal axis is a neuroendocrine system that regulates stress responses, with corticotropin hormone receptor binding as a key step.
How does pH affect corticotropin hormone receptor binding?
Proton sensitivity of CRHR1 can alter POMC expression, indicating that local pH modulates receptor binding and signaling.
Conclusion
Corticotropin hormone receptor binding (GO:0031780) is a pivotal molecular function in the neuroendocrine stress response, with far-reaching implications for health and disease. The interaction between ligands such as CRH and ACTH and their receptors CRHR1, CRHR2, and MC2R initiates signaling cascades that control cortisol production, anxiety, and metabolism. Dysregulation of this binding is implicated in anxiety disorders, depression, adrenal insufficiency, and metabolic syndrome. Advances in CRISPR-based models and high-throughput methods are accelerating our understanding of the molecular details and providing new avenues for therapeutic intervention. EDITGENE stands ready to support researchers with tailored CRISPR services to explore this critical pathway.
References
- 1. Hellhammer DH et al.. 2009. Salivary cortisol as a biomarker in stress research.. Psychoneuroendocrinology 34(2):163-171 PMID: 19095358
- 2. Zhao XJ et al.. 1997. Corticotropin-releasing hormone-binding protein and its possible role in neuroendocrinological research.. Horm Metab Res 29(8):373-8 PMID: 9288573
- 3. Svec F. 1985. Glucocorticoid receptor regulation.. Life Sci 36(25):2359-66 PMID: 2989635
- 4. Nikodemova M et al.. 2002. Multiple sites of control of type-1 corticotropin releasing hormone receptor levels in the pituitary.. Arch Physiol Biochem 110(1-2):123-8 PMID: 11935409
- 5. Skutella T et al.. 1998. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety.. Neuroscience 85(3):795-805 PMID: 9639273
- 6. Kameda H et al.. 2019. Proton Sensitivity of Corticotropin-Releasing Hormone Receptor 1 Signaling to Proopiomelanocortin in Male Mice.. Endocrinology 160(2):276-291 PMID: 30535142
- 7. Kawabata K et al.. 2010. Suppressive effect of quercetin on acute stress-induced hypothalamic-pituitary-adrenal axis response in Wistar rats.. J Nutr Biochem 21(5):374-80 PMID: 19423323
- 8. Suda T et al.. 1990. Glucocorticoids decrease a binding of corticotropin-releasing hormone-binding protein in human plasma.. J Clin Endocrinol Metab 71(4):913-7 PMID: 2169481
